November 30, 2022
Life Sciences
  • Eisai Co. Ltd. and Biogen Inc.’s Alzheimer drug lecanemab slowed patients’ mental decline by 27 percent over 18 months, according to a trial presented at the Clinical Trials on Alzheimer’s Disease conference. However, more than one in five people using the drug showed serious side effects like brain swelling and bleeding, compared to 10 percent of people on a placebo, while two patients died. (Articles here, here, and here)